Patents by Inventor Jörg Vollmer
Jörg Vollmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180171338Abstract: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.Type: ApplicationFiled: February 5, 2018Publication date: June 21, 2018Applicant: Adiu Tide Pharmaceuticals GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg, Ulrike Samulowitz, Bernard O. Noll
-
Patent number: 8304396Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: GrantFiled: October 4, 2006Date of Patent: November 6, 2012Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH, Pfizer Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann, Marion Jurk, Grayson B. Lipford, Robert Rankin
-
Patent number: 8283328Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: GrantFiled: August 19, 2003Date of Patent: October 9, 2012Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Grayson Lipford, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Patent number: 8188254Abstract: The invention relates to a class of CpG immunostimulatory oligonucleotides containing a CpG immunostimulatory motif and a second motif which is capable of forming secondary structure, including duplex and higher order structures, in vitro and in vivo. The oligonucleotides of the invention are useful as adjuvants in vaccination. The oligonucleotides are also useful for inducing an immune response, inducing expression of a type I interferon (IFN), inducing expression of gamma interferon (IFN-?), and for treating a variety of conditions, including allergy, asthma, infection, and cancer.Type: GrantFiled: October 29, 2004Date of Patent: May 29, 2012Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg, Bernhard O. Noll
-
Publication number: 20110206719Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: March 14, 2011Publication date: August 25, 2011Applicants: COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, INC.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Publication number: 20110201672Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: September 14, 2010Publication date: August 18, 2011Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7998492Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.Type: GrantFiled: October 29, 2003Date of Patent: August 16, 2011Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Publication number: 20110135605Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having semi-soft backbone.Type: ApplicationFiled: November 15, 2010Publication date: June 9, 2011Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Publication number: 20100316659Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: December 9, 2009Publication date: December 16, 2010Applicants: COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, INC.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Publication number: 20100285041Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: ApplicationFiled: May 15, 2008Publication date: November 11, 2010Inventors: Eugen Uhlmann, Jörg Vollmer, Arthur Mertz Kreig
-
Patent number: 7795235Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: December 17, 2008Date of Patent: September 14, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20100183639Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: ApplicationFiled: November 10, 2009Publication date: July 22, 2010Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Patent number: 7662949Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: GrantFiled: November 22, 2006Date of Patent: February 16, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Publication number: 20090306177Abstract: Double-stranded short interfering ribonucleic acid (siRNA) are modified to reduce or eliminate their immunostimulatory effect without significantly affecting their gene silencing effect. Modified siRNA include one or more 2? sugar modifications and, optionally, internucleotide linkages on the sense strand. Compositions containing the modified siRNA and methods of making and using the modified siRNA are disclosed. New and previously characterized siRNA can be synthesized to incorporate modifications according to the invention.Type: ApplicationFiled: September 15, 2006Publication date: December 10, 2009Applicants: Coley Pharmaceutical GmbH, Qiagen GmbHInventors: Eugen Uhlmann, Marion Jurk, Joerg Vollmer, Christian Schetter, Martin Weber, Ioanna Andreou, Stefan Pitsch
-
Patent number: 7615539Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: GrantFiled: September 27, 2004Date of Patent: November 10, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Patent number: 7566703Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7271156Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.Type: GrantFiled: December 9, 2002Date of Patent: September 18, 2007Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Jörg Vollmer, Christian Schetter